Page last updated: 2024-12-10

xanthatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

xanthatin: a phytogenic antineoplastic agent; RN given refers to (3aR-(3aalpha,7beta,8abeta))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	5281511
CHEBI ID	10058
MeSH ID	M0077917

Synonyms (25)

Synonym
26791-73-1
xanthatin
chebi:10058 ,
(3ar,7s,8as)-7-methyl-3-methylidene-6-[(e)-3-oxobut-1-enyl]-4,7,8,8a-tetrahydro-3ah-cyclohepta[b]furan-2-one
unii-298x1n12ls
3,3a,4,7,8,8a-hexahydro-7-methyl-3-methylene-6-(3-oxo-1-butenyl)-2h-cyclohepta(b)furan-2-one
298x1n12ls ,
2h-cyclohepta(b)furan-2-one, 3,3a,4,7,8,8a-hexahydro-7-methyl-3-methylene-6-((1e)-3-oxo-1-buten-1-yl)-, (3ar,7s,8as)-
xanthatin, (-)-
xanthatin [mi]
(-)-xanthatin
AC-34070
bdbm233119
xanthatin (2)
AKOS037514876
HY-N3032
(3ar,7s,8as)-7-methyl-3-methylene-6-((e)-3-oxobut-1-en-1-yl)-3,3a,4,7,8,8a-hexahydro-2h-cyclohepta[b]furan-2-one
mfcd17214852
Q27108568
CS-0023046
BS-50231
A877137
(3ar,7s,8as)-7-methyl-3-methylidene-6-[(1e)-3-oxobut-1-en-1-yl]-2h,3h,3ah,4h,7h,8h,8ah-cyclohepta[b]furan-2-one
DTXSID001317668
BBA79173

Research Excerpts

Overview

Xanthatin is a plant-derived bioactive sesquiterpene lactone from the Xanthium strumarium L. It has been used as a traditional Chinese medicine.

Excerpt	Reference	Relevance
"Xanthatin is a plant-derived bioactive sesquiterpene lactone from the Xanthium strumarium L., and it has been used as a traditional Chinese medicine. "	( TMT-Based Quantitative Proteomic Analysis Identified Proteins and Signaling Pathways Involved in the Response to Xanthatin Treatment in Human HT-29 Colon Cancer Cells. Chen, Z; Geng, Y; Li, L; Liu, P; Shen, A; Zhang, L, 2022)	2.37
"Xanthatin is an active sesquiterpene lactone isolated from Xanthium strumarium L."	( Xanthatin inhibits non-small cell lung cancer proliferation by breaking the redox balance. Geng, Y; Liu, P; Liu, Y; Xie, Y; Zhang, L; Zhu, X, 2022)	2.89
"Xanthatin (XT) is a sesquiterpene lactone isolated from the Chinese herb Xanthium, which belongs to the Asteraceae family. "	( Xanthatin Alleviates LPS-Induced Inflammatory Response in RAW264.7 Macrophages by Inhibiting NF-κB, MAPK and STATs Activation. Chen, W; Liu, Y; Wei, K; Yu, H; Zheng, F, 2022)	3.61
"Xanthatin is a sesquiterpene lactone monomer compound purified from the traditional Chinese herb Xanthium strumarium L."	( Xanthatin suppresses pancreatic cancer cell growth via the ROS/RBL1 signaling pathway: In vitro and in vivo insights. Geng, Y; Hou, X; Liu, P; Liu, Y; Xie, Y; Zhang, L; Zhang, X, 2023)	3.07
"Xanthatin (XT) is a bioactive compound derived from Xanthium strumarium L, and we developed a polymeric micelle (PM) that is dendritic cells (DCs)-specific targeting delivery system loading XT (NGR-XT-PM) based on a cyclic peptide moiety (NGR) to render DCs maturation-resistant for therapy of refractory AR."	( CD13-specific ligand facilitates Xanthatin nanomedicine targeting dendritic cells for therapy of refractory allergic rhinitis. Chu, X; Liu, C; Sun, C; Wang, C; Xia, M; Xu, J; Xu, X; Yu, R; Zhao, M; Zheng, X, 2020)	1.56
"Xanthatin (Xa) is a bicyclic sesquiterpene lactone identified from the plant Xanthium L. "	( Xanthatin synergizes with cisplatin to suppress homologous recombination through JAK2/STAT4/BARD1 axis in human NSCLC cells. Gao, Y; Guan, H; Yang, S; Zhang, J; Zhou, J, 2021)	3.51
"Xanthatin is an active sesquiterpene lactone isolated from Xanthium strumarium L."	( Xanthatin inhibits human colon cancer cells progression via mTOR signaling mediated energy metabolism alteration. Chen, Z; Geng, Y; Li, L; Liu, P; Liu, Y; Xie, Y; Zhang, L, 2022)	2.89

Actions

Excerpt	Reference	Relevance
"Xanthatin may inhibit the proliferation of pancreatic cancer cells and trigger apoptosis through the ROS/RBL1 signaling pathway."	( Xanthatin suppresses pancreatic cancer cell growth via the ROS/RBL1 signaling pathway: In vitro and in vivo insights. Geng, Y; Hou, X; Liu, P; Liu, Y; Xie, Y; Zhang, L; Zhang, X, 2023)	3.8

Treatment

Excerpt	Reference	Relevance
"The xanthatin treatment group exhibited a lower protein expression level of VEGF and increased protein expression level of PEDF, compared with the PBS treatment group."	( Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway. Jiang, N; Ma, MY; Shao, Y; Shen, M; Shi, C; Yang, QC; Ye, L; Yuan, Q; Zhou, XZ; Zhu, PW, 2018)	2.4

Pharmacokinetics

Excerpt	Reference	Relevance
"A sensitive, specific and rapid ultra high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method has been established to study pharmacokinetic properties of xanthatin."	( Determination of xanthatin by ultra high performance liquid chromatography coupled with triple quadrupole mass spectrometry: application to pharmacokinetic study of xanthatin in rat plasma. Cai, B; Chen, Z; Li, H; Li, W; Liu, X; Weng, Z; Wu, Y; Xie, D; Yan, C, 2014)	0.93

Bioavailability

Excerpt	Reference	Relevance
" Eventually, the bioavailability of XA was increased."	( A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin. Chen, R; Chen, Z; Li, W; Lin, S; Wu, L; Zhou, Y; Zhu, C; Zhu, X, 2020)	0.78

Dosage Studied

Excerpt	Relevance	Reference
" Solid oral dosage forms based on xanthatin were designed and assayed on rats."	( Determination and assay validation of the bioactive sesquiterpene lactone xanthatin isolated from Xanthium cavanillesii using capillary electrophoresis. Acosta, G; Favier, LS; Gomez, MR; María, AO; Tonn, CE, 2006)	0.84

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
sesquiterpene lactone	Any member of a diverse class of complex, multicyclic phytochemicals showing a variety of skeleton arrangements and bioactivities, and having in common a sesquiterpenoid structure including a lactone ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	6.5842	0.0052	9.4661	32.9993	AID1347411
Interferon beta	Homo sapiens (human)	Potency	6.5842	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID321377	Inhibition of iNOS expression in LPS-stimulated mouse BV2 cells at 20 uM after 20 hrs by Western blot analysis	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321376	Inhibition of NO production in LPS-activated mouse BV2 cells by ELISA	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321379	Inhibition of iNOS mRNA expression in LPS-stimulated mouse BV2 cells at 20 uM after 4 hrs by RT-PCR	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321378	Inhibition of COX2 expression in LPS-stimulated mouse BV2 cells after 20 hrs by Western blot analysis	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321382	Inhibition of NF-kappaB activity in LPS-stimulated mouse BV2 cells at 10 uM after 1 hr by luciferase reporter gene assay	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321381	Inhibition of IkappaB alpha degradation in LPS-induced mouse BV2 cells at 20 uM after 30 mins by Western blot analysis	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321380	Inhibition of COX2 mRNA expression in LPS-stimulated mouse BV2 cells at 20 uM after 4 hrs by RT-PCR	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID1802940	Fluorescence-Based PFTase Inhibition Assay from Article 10.3109/14756360903169592: \\Semisynthesis of alpha-methyl-gamma-lactones and in vitro evaluation of their activity on protein farnesyltransferase.\\	2010	Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 25, Issue:2	Semisynthesis of alpha-methyl-gamma-lactones and in vitro evaluation of their activity on protein farnesyltransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (3.70)	18.7374
1990's	2 (3.70)	18.2507
2000's	6 (11.11)	29.6817
2010's	25 (46.30)	24.3611
2020's	19 (35.19)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	26.03 (24.57)
Research Supply Index	4.03 (2.92)
Research Growth Index	5.38 (4.65)
Search Engine Demand Index	29.35 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (26.03)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (1.82%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	54 (98.18%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	7.6	1	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
furan furan : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing four carbons and one oxygen, with formula C4H4O. It is a toxic, flammable, low-boiling (31degreeC) colourless liquid.	2.31	1	furans; mancude organic heteromonocyclic parent; monocyclic heteroarene	carcinogenic agent; hepatotoxic agent; Maillard reaction product
2-naphthol 2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.	2.25	1	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.17	1	dialdehyde	biomarker
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	3.05	4	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.02	1	metal allergen; nickel group element atom; platinum group metal atom
etoposide [no description available]	2.08	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
dehydroleucodine dehydroleucodine: has antimicrobial activity; RN given refers to (3aS-(3aalpha,9aalpha,9bbeta))-isomer	2.54	2
p-methoxy-n-methylphenethylamine p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.	2.54	2	aromatic ether; secondary amino compound	metabolite
sesquiterpenes [no description available]	3.34	6
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.06	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	2.25	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	2.31	1	oligopeptide
ngr peptide [no description available]	2.25	1
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	2.07	1	benzoxazole
xanthinosin xanthinosin: a potential anticancer agent from Xanthium strumarium	7.99	4

Condition	Relationship Strength	Studies
Cancer of Colon [description not available]	3.1	4
Colonic Neoplasms Tumors or cancer of the COLON.	3.1	4
Cancer of the Retina [description not available]	2.31	1
Eye Cancer, Retinoblastoma [description not available]	2.31	1
Retinoblastoma A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)	7.31	1
Carcinoma, Non-Small Cell Lung [description not available]	3.42	6
Cancer of Lung [description not available]	3.42	6
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.42	6
Lung Neoplasms Tumors or cancer of the LUNG.	3.42	6
Innate Inflammatory Response [description not available]	2.96	3
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.96	3
Glial Cell Tumors [description not available]	3.68	2
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	3.68	2
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.6	1
Cancer of Pancreas [description not available]	2.6	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.6	1
Experimental Neoplasms [description not available]	2.25	1
Central Nervous System Neoplasm [description not available]	2.25	1
Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.	2.25	1
Allergic Rhinitis [description not available]	7.25	1
Rhinitis, Allergic An inflammation of the NASAL MUCOSA triggered by ALLERGENS.	2.25	1
Asthma, Bronchial [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.69	2
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	7.25	1
Cancer of Stomach [description not available]	2.53	2
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.53	2
Cancer of Prostate [description not available]	2.31	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.31	1
Mast Cell Activation Disease [description not available]	2.31	1
Gastric Ulcer [description not available]	2.49	2
Mastocytosis A rare neoplastic disorder characterized by a clonal proliferation of MAST CELLS, associated with KIT-D816 mutations, and accompanied by aberrant mast cell activation. The abnormal increase of MAST CELLS may occur in only the skin (MASTOCYTOSIS, CUTANEOUS), in extracutaneous tissues involving multiple organs (MASTOCYTOSIS, SYSTEMIC), or in solid tumors (MASTOCYTOMA).	2.31	1
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	2.49	2
Angiogenesis, Pathologic [description not available]	2.82	3
Corneal Angiogenesis [description not available]	2.17	1
Corneal Neovascularization New blood vessels originating from the corneal blood vessels and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.	7.17	1
Hepatocellular Carcinoma [description not available]	7.89	3
Cancer of Liver [description not available]	2.89	3
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.89	3
Liver Neoplasms Tumors or cancer of the LIVER.	2.89	3
Colorectal Cancer [description not available]	2.21	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.21	1
B16 Melanoma [description not available]	2.08	1
Breast Cancer [description not available]	2.78	3
Breast Neoplasms Tumors or cancer of the human BREAST.	2.78	3
Mast-Cell Leukemia [description not available]	2.07	1
Leukemia, Mast-Cell A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of	2.07	1
Carcinoma, Anaplastic [description not available]	2.07	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	7.07	1
Fungal Diseases [description not available]	2.07	1
Infections, Pseudomonas [description not available]	2.07	1
Infections, Staphylococcal [description not available]	2.07	1
Mycoses Diseases caused by FUNGI.	2.07	1
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.07	1
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2.07	1
Leukemia L 1210 [description not available]	1.98	1
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	1.98	1

chemdatabank.com